Related Experiment Video
Updated: Jul 15, 2026
09:12
Isolation of Adeno-Associated Viral Vectors Through a Single-Step and Semi-Automated Heparin Affinity Chromatography Protocol
Published on: April 5, 2024
European clinical experience with REPEL-CV
Christian Schreiber1, Andreas Boening, Martin Kostolny
1German Heart Center Munich, Department for Cardiothoracic Surgery, Lazarettstrasse 36, 80636 Munich, Germany. schreiber@dhm.mhn.de
Expert Review of Medical Devices
|May 10, 2007
Summary
REPEL-CV effectively reduced severe postoperative adhesions in pediatric cardiovascular surgery patients. This feasibility study demonstrated promising results for preventing adhesions in staged sternotomy procedures.
Area of Science:
- Cardiovascular Surgery
- Medical Devices
- Adhesion Prevention
Background:
- Postoperative adhesions are a significant complication in cardiovascular surgery, particularly in pediatric patients undergoing staged procedures.
- Developing effective strategies to prevent adhesions is crucial for improving patient outcomes and reducing re-intervention rates.
Purpose of the Study:
- To evaluate the clinical feasibility and safety of REPEL-CV in reducing postoperative adhesions in pediatric patients undergoing cardiovascular surgery.
- To assess the incidence and severity of adhesions during subsequent sternotomy procedures.
Main Methods:
- A feasibility study was conducted in Europe involving pediatric patients requiring staged cardiovascular sternotomy.
- REPEL-CV was used to reduce adhesions between initial and subsequent sternotomy procedures (2-8 months apart).
- Adhesion severity was assessed during the second sternotomy procedure.
Main Results:
- 13 out of 15 patients (86.7%) had no Grade 3 ('severe') adhesions at the second sternotomy.
- The mean percentage of the surgical site with severe adhesions was 11%.
- Five serious adverse events occurred, all unrelated to the REPEL-CV device.
Conclusions:
- REPEL-CV demonstrated a favorable safety profile in this pediatric cardiovascular surgery cohort.
- The study further supports the effectiveness of REPEL-CV in reducing severe postoperative adhesions.
- REPEL-CV shows potential as a valuable tool for adhesion prevention in pediatric cardiovascular surgery.
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:28Antimicrobial Effectiveness
The effectiveness of antimicrobial agents depends on various factors influencing their ability to eliminate microbial populations. Larger microbial populations require more time for complete eradication, emphasizing the importance of population size analysis when evaluating antimicrobial efficacy.Microbial resistance to antimicrobial agents varies significantly. Highly resilient microorganisms include endospores, gram-negative bacteria, and non-enveloped viruses, while prions are exceptionally...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...